Kodiak Sciences announced positive results from a second Phase 3 trial of Zenkuda (tarcocimab tedromer), an experimental treatment for vision loss that outperformed a sham procedure. The drug represents a significant reboot for Kodiak after previous setbacks in the program.
The Phase 3 trial evaluated tarcocimab tedromer in patients with vision loss, with the treatment demonstrating superiority over a control sham procedure. This marks the second successful Phase 3 study for the drug, providing additional validation for its efficacy profile.